Revolution Medicines rises after pancreatic cancer drug doubles survival in study
01/06/2026 11:45
BUZZ-Revolution Medicines rises after pancreatic cancer drug doubles survival in study ** Shares of biotech Revolution Medicines RVMD.O rise 8.7% to $171.22 premarket
** In a 500-patient late-stage trial, experimental pancreatic cancer drug daraxonrasib doubled survival, compared with chemotherapy, and improved symptoms enough that some patients could resume activities they had previously abandoned
** In patients with advanced pancreatic cancer who had failed one round of chemotherapy, the once-daily pill daraxonrasib cut the risk of death by 60% compared with standard chemotherapy
** As of last close, RVMD stock was up over 97% YTD
(Reporting by Padmanabhan Ananthan)
Recent news on Revolution Medicines
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
Brief: CHMP Recommends Granting Marketing Authorisation For Rasonque For Metastatic Pancreatic Cancer In EU
Revolution Medicines wins EU committee backing for pancreatic cancer treatment (updated)
EMA recommends approval of Revolution's pancreatic cancer drug
Revolution Medicines falls on pancreatic cancer drug data concerns